我院铜绿假单胞菌临床分布及耐药性分析  

Clinical Distribution and Drug Resistance of Pseudomonas Aeruginosa in 2017 in our Hospital

作　　者：黄蓉 李任翔[1] 邵寅[1] 张杰[1] 刘晨晖[1] 王玲[1] 庞丽燕 HUANG Rong;LI Ren-xiang;SHAO Yin;ZHANG Jie;LIU Chen-hui;WANG Ling;PANG Li-yan(Jingmen first people’s hospital,Jingmen Hubei)

机构地区：[1]荆门市第一人民医院

出　　处：《世界最新医学信息文摘》2018年第72期11-13,共3页World Latest Medicine Information Electronic Version

基　　金：2015年度荆门市引导性科研项目(立项编号:YDKY2015008)

摘　　要：目的分析我院铜绿假单胞菌的耐药性特点,为临床治疗提供资料,更好地控制及治疗铜绿假单胞菌感染。方法对我院2017年1月1日至2017年12月31日临床分离的158例铜绿假单胞菌药敏试验结果进行统计分析。结果铜绿假单胞菌感染主要集中在ICU、呼吸内科及神经外科,分别占37.34%、19.62%、13.92%。铜绿假单胞菌菌株主要来源于痰液标本,占75.32%。铜绿假单胞菌对阿米卡星耐药率最低,为10.76%,其次分别是妥布霉素(22.78%)、左氧氟沙星(24.68%)、头孢他啶(27.22%)、环丙沙星(27.85%)、庆大霉素(31.64%)、头孢吡肟(33.54%)、哌拉西林/他唑巴坦(36.08%)、亚胺培南(39.87%)。结论我院铜绿假单胞菌对多种抗菌药物的敏感程度不同,临床应加强其耐药性监测及针对性管理,合理使用抗菌药物,以减少耐药菌株的产生。Objective To analyze the drug resistance of Pseudomonas aeruginosa in our hospital, provide data for clinical treatment, control and treat Pseudomonas aeruginosa infection.Methods The resistance feature in 158 strains of Pseudomonas aeruginosa collected in our hospital from January 1 st, 2017 to December 31 st, 2017 were statistically analyzed. Results Pseudomonas aeruginosa infection was mainly concentrated in ICU,respiratory medicine and neurosurgery,accounting for 37.34%,19.62% and13.92%,respectively.Pseudomonas aeruginosa strains mainly originated from sputum samples, accounting for 75.32%. Pseudomonas aeruginosa has the lowest resistance to amikacin, accounting for 10.76%, followed by tobramycin(22.78 %), levofloxacin(24.68%), ceftazidine(27.22 %), ciprofloxacin(27.85 %), gentamicin(31.64%), cefepime(33.54%), piperacillin/tazobactam(36.08 %) and Imipenem(39.87 %). Conclusion The sensitivity of Pseudomonas aeruginosa to various antimicrobial agents is different in our hospital.Clinical drug resistance monitoring and targeted management should be strengthened,Rational use of antimicrobial agents to reduce the production of drug-resistant strains.

关 键 词：铜绿假单胞菌 临床分布 耐药性 

分 类 号：R446.5[医药卫生—诊断学]